Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Pharvaris announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from 12-13 April 2024, in Arlington, Texas, United States of America.
Presentation details:
Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Format: Digital Abstract Display Board
Date, time: Saturday 13 April, 11:00-11:20am CDT (12:00-12:20pm EDT)
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: John Anderson MD
Format: E-Poster Presentation
Date, time: Saturday 13 April 13, 11:20 a.m.-12:00pm CDT (12:20-1:00pm EDT)
(Source: Pharvaris)
